WallStSmart

Immuron Ltd ADR (IMRN)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Immuron Ltd ADR generates 908% more annual revenue ($7.48M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -62.1%. IMRN earns a higher WallStSmart Score of 28/100 (F).

IMRN

Avoid

28

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 5.3
Piotroski: 2/9Altman Z: -9.18

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IMRN1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Areas to Watch

IMRN4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$9.93M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IMRN

The strongest argument for IMRN centers on Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : IMRN

The primary concerns for IMRN are Revenue Growth, EPS Growth, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

IMRN profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.38 — expect wider price swings.

IMRN is growing revenue faster at 4.8% — sustainability is the question.

IMRN generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

IMRN scores higher overall (28/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Immuron Ltd ADR

HEALTHCARE · BIOTECHNOLOGY · USA

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?